Redefining Performance in Established NSAIDs

Oxford PharmaScience has developed OXPzero™, a proprietary NSAID performance platform that separates speed of onset from peak exposure. By controlling how established medicines are released and absorbed, OXPzero™ enables clinically validated differentiation across OTC and prescription markets.

Implemented using proprietary Layered Double Hydroxide (LDH) chemistry, the platform delivers rapid onset, controlled systemic exposure, intrinsic taste masking, and compatibility with multiple consumer-relevant dosage formats.